Nationwide non-profit funding research and delivering cancer information and services
Vivani Medical is developing a long-acting semaglutide implant to deliver GLP-1 therapy over months, potentially replacing injections. Novo Nordisk is evaluating the device to improve adherence and reduce weight regain, but regulatory and cost questions remain as trials proceed.
Federal SNAP reform has tightened eligibility and shifted costs to states, triggering a sharp drop in participation and putting pressure on food banks. Arizona records the largest decline, with state processes becoming more burdensome and delivery times longer as programs adjust. Projections warn of continued reductions without congressional action.
CMS has announced an end to the Part D subsidy at the end of 2026, signaling higher prescription costs for roughly 25 million beneficiaries. Insurers say pricing for 2027 will reflect the change, potentially widening premiums by up to $20 a month for some plans, while experts warn about broader affordability pressures and plan take-up shifts.
Sims, eight years after a melanoma diagnosis, is warning that tanning is surging again among young people online. Experts say tanning beds dramatically raise melanoma risk, with DNA mutations more likely in users. Reports show 100,000+ melanomas expected in 2026; influencers promote tanning, while dermatologists stress there is no safe tan.
Athletes and patients have urged Downing Street to appoint a national brain cancer lead and boost research funding. The Rare Cancers Bill is seen as a step forward but not enough, with calls for faster action in light of Commonwealth Games coverage and ongoing treatment campaigns.
Sydney Towle, a 26-year-old influencer known for documenting her battle with cholangiocarcinoma on TikTok, has died after a three-year fight. Family posted that she died peacefully in hospice care. Her journey drew a large online following and spotlighted the realities of cancer among young people.
The FDA has approved daraxonrasib (Rasonque), a once-daily pill from Revolution Medicines, for adults with metastatic pancreatic cancer who have received prior therapy or cannot take combination chemotherapy. A 500‑patient trial has shown median survival of 13.2 months versus 6.7 months for chemotherapy; a 30‑day supply will cost about $39,800 and expanded access has already treated thousands.
GLP-1 medications are being increasingly prescribed off-label to children aged 8–11 in the US, despite no FDA approval for under-12s. A NYU Langone study shows a dramatic rise in June 2026, while experts warn about long-term effects and the broader obesity crisis.
This week has seen several medical research and regulatory developments. Insilico Medicine has reported that its experimental drug rentosertib changed blood‑protein patterns that aging clocks read as three to four years younger in a small trial. Stanford teams have published studies showing they can grow hindbrain neurons separately and implant human cortical organoids into mice. The US health department has appointed permanent directors for three FDA centers.